| P2093 | author name string | Klaus J Erb | |
| | Frank Kalkbrenner | |
| | Melanie Werner-Klein | |
| P2860 | cites work | Safety and tolerability of ultra-Rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma | Q57629036 |
| | A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract | Q57909865 |
| | A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. | Q53854248 |
| | Sublingual immunotherapy. | Q54105175 |
| | Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1 | Q56827917 |
| | Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season | Q56827955 |
| | PROPHYLACTIC INOCULATION AGAINST HAY FEVER | Q57255078 |
| | Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity | Q57267001 |
| | In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy | Q28189640 |
| | Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature | Q33204109 |
| | Specific immunotherapy in asthma | Q33757879 |
| | Long-term clinical efficacy of grass-pollen immunotherapy | Q33870492 |
| | Safety of sublingual-swallow immunotherapy in children and adults | Q33870761 |
| | Novel therapy for asthma | Q34074657 |
| | Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. | Q34170327 |
| | Analyzing meta-analyses of specific immunotherapy in the treatment of asthma | Q34321321 |
| | Appropriate and inappropriate use of immunotherapy | Q34321339 |
| | Allergic rhinitis and its impact on asthma | Q34438438 |
| | Immune mechanisms of allergen-specific sublingual immunotherapy | Q34484071 |
| | IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy | Q34499562 |
| | In vivo instruction of suppressor commitment in naive T cells | Q34548023 |
| | Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper | Q34754637 |
| | T-cell tolerance in allergic response. | Q34778048 |
| | Noninjection routes for immunotherapy | Q35087289 |
| | Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs | Q35178388 |
| | Renaissance of the blocking antibody concept in type I allergy | Q35557996 |
| | Is sublingual immunotherapy clinically effective? | Q35643305 |
| | Mechanisms of immunotherapy. | Q35811876 |
| | Activated CD4+CD25+ T cells selectively kill B lymphocytes | Q35848308 |
| | Efficacy and safety of sublingual immunotherapy | Q35849524 |
| | Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis | Q35970094 |
| | Comparison of the clinical efficacy and safety of subcutaneous and sublingual immunotherapy: methodological approaches and experimental results | Q36004400 |
| | Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. | Q36073821 |
| | The safety of sublingual-swallow immunotherapy: an analysis of published studies | Q36130311 |
| | The role of adjuvants in the development of mucosal vaccines | Q36194084 |
| | CD28/CTLA-4--CD80/CD86 and ICOS--B7RP-1 costimulatory pathway in bronchial asthma | Q36346464 |
| | Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells | Q36354420 |
| | Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages | Q36361336 |
| | Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium | Q36362334 |
| | Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals | Q36362607 |
| | The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model | Q36365507 |
| | Sublingual immunotherapy in the treatment of children | Q36515380 |
| | Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study | Q39581669 |
| | Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood | Q40488834 |
| | Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases | Q40517747 |
| | Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis | Q40523833 |
| | Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study | Q40544021 |
| | Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). | Q40588482 |
| | Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. | Q40593688 |
| | Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. | Q40601643 |
| | Grass pollen immunotherapy decreases the number of mast cells in the skin. | Q40631611 |
| | Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and jun B: relevance to immunotherapy | Q40637631 |
| | Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. | Q40656273 |
| | Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. | Q40668250 |
| | A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract | Q40701091 |
| | Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen | Q41022355 |
| | Nasal mucosal hyperpermeability to macromolecules in atopic rhinitis and extrinsic asthma | Q41068413 |
| | Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule | Q42662221 |
| | Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity | Q43561164 |
| | Elevated secretion of myeloperoxidase by neutrophils from asthmatic patients: the effect of immunotherapy. | Q43570354 |
| | Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study | Q43646876 |
| | Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. | Q43795644 |
| | Peptidase activity on the surface of the porcine buccal mucosa | Q43919783 |
| | Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites | Q44290592 |
| | IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy | Q44429951 |
| | Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. | Q44467274 |
| | Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites | Q44488880 |
| | Monitoring of seasonal variability in bronchial hyper-responsiveness and sputum cell counts in non-asthmatic subjects with rhinitis and effect of specific immunotherapy | Q44512048 |
| | Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. | Q44574133 |
| | Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract | Q44773540 |
| | Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers | Q45009815 |
| | Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis | Q45088215 |
| | Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. | Q45949848 |
| | A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. | Q46469365 |
| | Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis | Q46892026 |
| | Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. | Q47315232 |
| | Langerhans cells from human oral epithelium are more effective at stimulating allogeneic T cells in vitro than Langerhans cells from skin | Q47594341 |
| | Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization | Q47702181 |
| | Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers | Q47715881 |
| | Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects | Q47766233 |
| | Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years | Q47795423 |
| | Safety of sublingual immunotherapy with a monomeric allergoid in very young children. | Q47886315 |
| | Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis | Q47938843 |
| | A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation | Q47988492 |
| | Bacillus Calmette-Guérin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy | Q47988526 |
| | Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. | Q50621222 |
| | Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. | Q51686636 |
| | Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. | Q51719532 |
| | Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. | Q51727137 |
| | Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. | Q52553246 |
| | Requirement of CD28-CD86 costimulation for allergen-specific T cell proliferation and cytokine expression. | Q52904932 |
| | Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. | Q52940754 |
| | A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. | Q52942005 |
| | Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. | Q52972998 |
| | Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. | Q53551598 |
| | Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. | Q53697543 |
| | Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. | Q53729251 |
| | Early effect of ultrarush venom immunotherapy on the IgG antibody response. | Q53796451 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 599-612 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Expert Opinion on Drug Delivery | Q5421203 |
| P1476 | title | Sublingual immunotherapy of allergic diseases | |
| P478 | volume | 3 | |